Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
41
ALNY Quote, Financials, Valuation and Earnings
Last price:
$397.66
Seasonality move
:
0.84%
Day range:
$397.25 - $402.44
52-week range:
$205.87 - $495.55
Dividend yield:
0%
P/E ratio:
1,653.43x
P/S ratio:
16.31x
P/B ratio:
224.61x
Volume:
768.9K
Avg. volume:
1.5M
1-year change:
68.99%
Market cap:
$52.5B
Revenue:
$2.2B
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.72 | 98.51% | -58.59% | $491.92 |
|
BBIO
BridgeBio Pharma, Inc.
|
$148.1M | -$0.62 | 2418.14% | -55.45% | $86.56 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.75 | -5.28% | -4.28% | $182.07 |
|
GKOS
Glaukos Corp.
|
$129.5M | -$0.21 | 22.71% | -65.32% | $124.07 |
|
INSM
Insmed, Inc.
|
$174.3M | -$1.36 | 66.86% | -2.57% | $214.78 |
|
PFE
Pfizer Inc.
|
$16.9B | $0.56 | -4.67% | 694.29% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$397.65 | $491.92 | $52.5B | 1,653.43x | $0.00 | 0% | 16.31x |
|
BBIO
BridgeBio Pharma, Inc.
|
$76.49 | $86.56 | $14.7B | -- | $0.00 | 0% | 41.19x |
|
BIIB
Biogen, Inc.
|
$175.99 | $182.07 | $25.8B | 16.05x | $0.00 | 0% | 2.66x |
|
GKOS
Glaukos Corp.
|
$112.91 | $124.07 | $6.5B | -- | $0.00 | 0% | 13.63x |
|
INSM
Insmed, Inc.
|
$174.04 | $214.78 | $37.1B | -- | $0.00 | 0% | 74.06x |
|
PFE
Pfizer Inc.
|
$24.90 | $28.62 | $141.6B | 14.51x | $0.43 | 6.91% | 2.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.206 | 4.61% | 2.37x |
|
BBIO
BridgeBio Pharma, Inc.
|
350.59% | 0.558 | 27% | 3.52x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.665 | 32.07% | 1.77x |
|
GKOS
Glaukos Corp.
|
11.94% | 1.580 | 2.23% | 4.35x |
|
INSM
Insmed, Inc.
|
44.07% | 2.489 | 2.43% | 4.18x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BBIO
BridgeBio Pharma, Inc.
|
$113.4M | -$136.4M | -109.98% | -- | -112.97% | -$112.4M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
GKOS
Glaukos Corp.
|
$104.7M | -$16.4M | -10.16% | -11.73% | -12.26% | -$11.7M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Alnylam Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ALNY or BBIO?
BridgeBio Pharma, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -153.22%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat BridgeBio Pharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M -
What do Analysts Say About ALNY or BBIO?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 23.71%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $86.56 which suggests that it could grow by 13.16%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than BridgeBio Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 BBIOBridgeBio Pharma, Inc.15 1 0 -
Is ALNY or BBIO More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.877%.
-
Which is a Better Dividend Stock ALNY or BBIO?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or BBIO?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,653.43x while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.31x versus 41.19x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.31x 1,653.43x $1.2B $251.1M BBIOBridgeBio Pharma, Inc.41.19x -- $120.7M -$184.9M
-
Which has Higher Returns ALNY or BIIB?
Biogen, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 19%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 23.71%. On the other hand Biogen, Inc. has an analysts' consensus of $182.07 which suggests that it could grow by 3.45%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 BIIBBiogen, Inc.14 18 1 -
Is ALNY or BIIB More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.
-
Which is a Better Dividend Stock ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,653.43x while Biogen, Inc.'s PE ratio is 16.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.31x versus 2.66x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.31x 1,653.43x $1.2B $251.1M BIIBBiogen, Inc.2.66x 16.05x $2.5B $466.5M
-
Which has Higher Returns ALNY or GKOS?
Glaukos Corp. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -12.16%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Glaukos Corp.'s return on equity of -11.73%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B GKOSGlaukos Corp.78.41% -$0.28 $873.9M -
What do Analysts Say About ALNY or GKOS?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 23.71%. On the other hand Glaukos Corp. has an analysts' consensus of $124.07 which suggests that it could grow by 9.89%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Glaukos Corp., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Glaukos Corp..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 GKOSGlaukos Corp.11 0 1 -
Is ALNY or GKOS More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.203%.
-
Which is a Better Dividend Stock ALNY or GKOS?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or GKOS?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than Glaukos Corp. quarterly revenues of $133.5M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Glaukos Corp.'s net income of -$16.2M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,653.43x while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.31x versus 13.63x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.31x 1,653.43x $1.2B $251.1M GKOSGlaukos Corp.13.63x -- $133.5M -$16.2M
-
Which has Higher Returns ALNY or INSM?
Insmed, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -259.95%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About ALNY or INSM?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 23.71%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 23.5%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 INSMInsmed, Inc.17 1 0 -
Is ALNY or INSM More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.
-
Which is a Better Dividend Stock ALNY or INSM?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or INSM?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,653.43x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.31x versus 74.06x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.31x 1,653.43x $1.2B $251.1M INSMInsmed, Inc.74.06x -- $142.3M -$370M
-
Which has Higher Returns ALNY or PFE?
Pfizer Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 21.32%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About ALNY or PFE?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $491.92, signalling upside risk potential of 23.71%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.95%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.14 7 0 PFEPfizer Inc.7 15 1 -
Is ALNY or PFE More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.325, which suggesting that the stock is 67.539% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock ALNY or PFE?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or PFE?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,653.43x while Pfizer Inc.'s PE ratio is 14.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 16.31x versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.16.31x 1,653.43x $1.2B $251.1M PFEPfizer Inc.2.26x 14.51x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
